Bachem has entered a strategic collaboration with Eli Lilly and Co. to develop and manufacture active pharmaceutical ingredients based on oligonucleotides, a rising new class of complex molecules.
 
Bachem will provide the engineering infrastructure and expertise to implement Lilly’s novel oligonucleotide manufacturing technology. Bachem will also provide R&D and production personnel at its facilities in Bubendorf, Switzerland, for the development and manufacture of GMP-grade material for Lilly’s oligonucleotide-based investigational medicines using Lilly’s technology.
 
Lilly commits to placing manufacturing projects with Bachem over the next seven years with increasing material supply demands following successful implementation of Lilly’s oligonucleotide manufacturing technology. The annual order volume has the potential to achieve around CHF 100 million, depending on Bachem reaching certain milestones and definite volumes ordered by Lilly.
 
“We are excited about the prospects that our strategic collaboration with Lilly has for innovating how oligonucleotides are manufactured. Investigational medicines based on synthetically accessible oligonucleotides hold great promise for patients suffering from a variety of diseases and we are proud to collaborate with Lilly in unlocking the potential of this new modality. This collaboration between Bachem and Lilly is an example of how the biopharma and CDMO industries can work together on innovative medicines that are developed and manufactured at scale and of high quality for patients in need. Our aim with this collaboration is to jointly develop tailored engineering and equipment solutions for oligonucleotides, thus improving quality and reducing manufacturing cost and time to market,” said Thomas Meier, CEO
 
Therapeutic oligonucleotides are short single or double-stranded fragments of DNA or RNA. Because of their unique properties, oligonucleotides as therapeutics open access to previously “undruggable” targets not accessible with small molecule drugs or biologics. Initially used within orphan diseases with small patient populations, scientific progress has led to a broad expansion of drug development projects on oligonucleotide-based therapeutics in the biopharma industry. This increasing demand and the promise of addressing larger patient groups require the production of oligonucleotide-based active pharmaceutical ingredients (API) at a larger scale and with new processing solutions.

Visit Bachem at CPhI NA booth 1609